Silex Systems Limited

The Business

Silex is not an enricher. It is a 51% equity holder in Global Laser Enrichment (GLE), a joint venture with Cameco (49%), plus the licensor of the underlying SILEX technology, earning a 7% royalty on GLE's gross revenue once GLE sells enriched uranium. GLE plans a commercial-scale Paducah Laser Enrichment Facility (PLEF) using 30 years of contracted depleted uranium tailings feedstock from the US Department of Energy. A small silicon isotope business, Q-Si, sits alongside but contributes negligibly today. There is no enrichment revenue yet.

Recent Performance

The share price has re-rated hard on the nuclear thematic and the October 2025 achievement of Technology Readiness Level 6 (TRL-6), an industrial-scale demonstration milestone. Reported revenue rose from A$12m in FY25 to A$21.6m in FY26, but this is government grants, cost recovery and milestone payments, not product sales. Net losses actually narrowed slightly over the same period, from A$43m to A$39m, as that revenue offset rising spend.

Outlook

Losses are expected to widen again over the next several years as Silex funds its share of GLE's pre-construction and early build costs, while revenue plateaus near current levels, still non-commercial in nature. Free cash outflow is set to deepen from here, and the share count is expected to grow as further capital raises fund construction ahead of any GLE product revenue. Earnings, in the conventional sense, are not expected to recover within this forecast horizon, because the company's economics depend on a facility that has not yet reached a final investment decision.

Key Risks

No third-generation laser enrichment technology has ever run commercially, and failure at scale would be the single most damaging outcome for shareholders, collapsing the value of the equity stake and the royalty stream alike. Construction of the multi-billion dollar enrichment facility will likely require further dilutive capital raises, meaningfully reducing existing shareholders' per-share economic interest over time. Separately, Cameco holds an option to lift its GLE stake from 49% to 51% by April 2028, which would cut Silex's economic interest in the joint venture roughly in half and is a material swing factor either way.

What to Watch

• H2 CY2028 TRL-7 progress/achievement — this is the thesis-defining event, testing whether laser separation holds up at commercial throughput rather than pilot scale.
• Q1 CY2027 NRC licence decision for PLEF — approval removes a major regulatory overhang; denial pushes the timeline out years.
• By April 2028 Cameco option decision — resolves whether Silex retains 51% or is diluted to 25% of GLE.

Latest Developments

TRL-6 was achieved on schedule in October 2025, and a A$149m capital raise has been completed to fund pre-FID (final investment decision) spending. Neither event resolves the core commercial economics question: no feasibility study has been released.

Company Description

Silex Systems is a technology holding company built around a single asset: its 51% stake in GLE, developed with Cameco (49%). GLE is commercialising SILEX, a laser-based uranium enrichment process, targeting a Paducah, Kentucky facility with an initial 4 million SWU (separative work unit, the standard measure of enrichment capacity) capacity and a path to 8 million SWU. Silex separately owns Q-Si, an early-stage silicon isotope business, and earns a 7% royalty on GLE's future gross revenue regardless of its equity stake. There is no commercial enrichment revenue today.

Where the Growth Is

The single most important driver, once it exists, is the GLE royalty: 7% of gross enrichment revenue, contributing nothing today but structured as a perpetual, capital-free income stream once PLEF reaches commercial operations. At GLE's projected steady-state revenue of A$700m-1,400m, this royalty alone could generate a meaningful, high-margin cash flow to Silex, independent of how the Cameco equity split resolves.

Competitive Position

SILEX has been classified by the US government since 2001, which blocks competitors from reverse-engineering it and removes any patent-expiry risk. GLE also holds a 30-year DOE contract for depleted uranium tailings feedstock, a cost advantage no other Western enricher has secured. Cameco's continued 49% co-investment, despite zero GLE revenue to date, signals confidence from an informed industry participant. If commercial economics are validated, these advantages look durable for 15 years or more. If they are not, none of this matters, because there is no fallback business.

Management & Capital Discipline

Management delivered TRL-6 on schedule and completed a A$149m raise, but has no track record of allocating capital to a commercial operation, because none exists yet. The honest observation: credibility is strong on engineering milestones and weak on commercial claims. The often-cited sub-A$30/lb enrichment cost target and 2030 commercial start have not been backed by any published feasibility study.

Financial Position

Silex holds cash of roughly A$181m with no debt, which funds pre-construction spending for around two to three years at current burn rates. That balance sheet gives management runway to reach key technology and regulatory milestones without an immediate raise, but it does not come close to funding the estimated A$2-3.5bn PLEF construction cost, meaning further dilution is a near-certainty rather than a risk.